Xeomin® and Gait Related Mobility After Stroke

Официальное название

Upper Extremity Injection of Xeomin® and Changes in Gait Related Mobility in Adults After Stroke

Обзор

The aim of the present pilot study is to evaluate the association between change in gait related mobility in ambulatory male and female adult hemiparetic patients before and 4-6-weeks after Xeomin® injection into the upper limb, using two standardized tests of physical function in outpatient rehabilitation that are widely used; the 10-meter walk test and the timed 'up and go' test (TUG).

Подробное описание

For this pilot study, the investigators hypothesize that there will be durational improvements in gait related mobility on the instrumented TUG and 10-meter walk tests 4-6-weeks post upper extremity Xeomin® injection. Physical function will be quantified as time to complete the instrumented TUG.

A one-group pretest-post-test experimental design will be used. Participants will be tested on the primary and secondary outcome measures before upper extremity injection with Xeomin® and 4 to 6 weeks thereafter. Additionally, participants will be contacted for an end of study visit via telephone approximately 12-weeks post Xeomin® injection to obtain information regarding any adverse events and gain insight into the therapeutic duration of the Xeomin®. The proposed duration of the study is 2 years to allow adequate time for screening, recruitment and follow-up.

Вмешательства

• Препарат Xeomin®
  To discover whether injection into the upper extremity with Xeomin® triggers improvements in gait-related mobility and quality of life in adults with hemiparesis secondary to stroke.

Первичные конечные точки

• Change in Instrumented Timed Up and Go test time [Срок оценки: Baseline and 4-6 weeks after Xeomin injection]

Вторичные конечные точки (9)

• Change in Ten-meter walk test time [Срок оценки: Baseline and 4-6 weeks after Xeomin injection]
• Change in Mini-Mental State Examination score [Срок оценки: Baseline and 4-6 weeks after Xeomin injection]
• Change in Quality of Life in Neurological Disorders (Neuro-QoL) Depression - Short Form score [Срок оценки: Baseline and 4-6 weeks after Xeomin injection]
• Change in Patient-Reported Outcomes Measurement Information System (PROMIS) General Life Satisfaction - Short Form 5a score [Срок оценки: Baseline and 4-6 weeks after Xeomin injection]
• Change in Brief Pain Inventory (BPI) - Short Form score [Срок оценки: Baseline and 4-6 weeks after Xeomin injection]
• Change in Neuro-QoL Satisfaction with Social Roles and Activities - Short Form score [Срок оценки: Baseline and 4-6 weeks after Xeomin injection]
• Change in Modified Ashworth Scale (MAS) score [Срок оценки: Baseline and 4-6 weeks after Xeomin injection]
• Change in Berg Balance Scale (BBS) score [Срок оценки: Baseline and 4-6 weeks after Xeomin injection]
• Change in Activities-Specific Balance (ABC) Scale score [Срок оценки: Baseline and 4-6 weeks after Xeomin injection]

Критерии участия

Критерии включения

• Diagnosis of hemiparesis and spasticity secondary to stroke with upper and lower limb spasticity and unilateral motor and/or sensory deficit
• No prior surgery to the lower limb
• Able to walk at least 10 meters without physical assistance from another person and without an assistive device
• Toe- ground clearance during swing phase without assistive device or orthoses
• No treatment with botulinum toxin within the past 4 months

Критерии исключения

• Passive range of motion at either the ankle, knee, or elbow joint less than 30 degrees
• Participants with uncorrected hearing impairment
• Weight bearing restrictions due to concurrent orthopedic injuries that would make ambulating with or without an assistive device unsafe
• Speech language expression deficit (e.g., aphasia)
• Absence of proprioception upon neurologic examination
• Presence of fixed contractures in the upper or lower extremities not correctable to neutral
• Other confounding neurological diagnoses or active acute illness (cancer, Parkinson's disease, multiple sclerosis)

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

США · 1 центр

• Carolinas Rehabilitation — Charlotte

Идентификаторы

NCT: NCT04908423 · IRB00082738 · BTX1.0

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗